Top Section/Ad
Top Section/Ad
Most recent
Calendar quirk could keep issuance going in December
◆ Praemia refis at a tighter coupon ◆ Schneider lands tight at the short end ◆ Minimal concessions needed
French biotech seeks to accelerate cancer vaccine program
◆ Single digit premiums offered ◆ Reverse Yankees dominating euro supply ◆ Floaters proving popular with multi-tranche issuers
More articles/Ad
More articles/Ad
More articles
-
Capital markets cheered the victory of president elect Joe Biden on Saturday, hopeful his presidency will prove more predictable than the four years of the Trump administration. As the US grapples with a resurgence of Covid-19 infections, sources say they are optimistic that Biden will provide more concrete plans to guide the nation through the pandemic. -
Three banks launched new senior deals in euros on Monday, taking advantage of a jubilant tone in the market following Joe Biden’s victory in the US presidential election. That sentiment received a further boost during the morning trading session when Pfizer and BioNTech revealed successful Covid-19 vaccine trials.
-
Target Healthcare, a care home real estate investment trust, has renegotiated £170m of loans, with the borrower using risk free rates instead of Libor as a benchmark.
-
Antengene Corp, a clinical stage biopharmaceutical company, has set its Hong Kong listing in motion. It has opened bookbuilding for an up to HK$2.79bn ($359.4m) IPO.
-
The Royal College of Surgeons England has sold £40m of private placements, to help finance the redevelopment of its headquarters in Lincoln’s Inn Fields in London.
-
The island nation of the Maldives received a fresh blow this week after Fitch Ratings downgraded the country by three notches to CCC due to external liquidity pressure and increasing debt burden.
